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Pregabalin has shown promise in the treatment of anxiety disorders. Previous functional
magnetic resonance imaging (fMRI) studies indicate agents used to treat anxiety, e.g.,
SSRIs and benzodiazepines, attenuate amygdala, insula, and medial prefrontal cortex
(mPFC) activation during emotional processing. Our prior study has shown that during
anticipation of an emotional stimulus, pregabalin attenuates amygdala and insula activation
but increases medial PFC activation. In this study, we examined whether, similar to
SSRIs and benzodiazepines, pregabalin attenuates amygdala, insula, and medial PFC
during emotional face processing. Sixteen healthy volunteers underwent a double-blind
within-subjects fMRI study investigating effects of placebo, 50mg, and 200mg pregabalin
on neural activation during an emotional face-matching task. Linear mixed model analysis
revealed that pregabalin dose-dependently attenuated left amygdala activation during
fearful face-matching and left anterior insula activation during angry face-matching. The
50mg dose exhibited more robust effects than the 200mg dose in the right anterior insula
and ventral ACC. Thus, pregabalin shares some similarity to SSRIs and benzodiazepines
in attenuating anger and fear-related insula and amygdala activation during emotional
face processing. However, there is evidence that a subclinical 50mg dose of pregabalin
produced more robust and widespread effects on neural responses in this paradigm than
the more clinically relevant 200mg dose. Taken together, pregabalin has a slightly different
effect on brain activation as it relates to anticipation and emotional face processing, which
may account for its unique characteristic as an agent for the treatment of anxiety disorders.
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INTRODUCTION
Anxiety disorders affect approximately one in five adults each
year in the United States (Kessler et al., 2005) and are associ-
ated with significant psychological and somatic distress as well
as increased healthcare costs for those afflicted (Hoffman et al.,
2008; Bereza et al., 2009; Johnston et al., 2009; Pirkola et al.,
2009). First line pharmacologic therapies include selective sero-
tonin reuptake inhibitors (SSRIs) and benzodiazepines. However,
SSRIs are associated with side effects such as weight gain and
sexual dysfunction, usually take 2–4 weeks to effect symptom
reduction, and often fail to produce full remission (Baldwin,
2008). Benzodiazepines have a more immediate effect on symp-
toms, but are associated with concerns regarding side effects
such as sedation and cognitive impairment, as well as potential
risks for abuse or dependence (McIntosh et al., 2004; Cloos and
Ferreira, 2009). Considering these issues, there remains consider-
able room to improve both the effectiveness and side effect profile
of pharmacologic anxiety treatment.
Pregabalin, currently marketed in the US for treatment of
fibromyalgia and neuropathic pain, has also shown promise as an
anxiolytic. Pregabalin has demonstrated anxiolytic effects in acute
paradigms(i.e., those investigating short-termeffects), suchaspre-
surgical anxiety (Nutt et al., 2008), and in the chronic treatment of
generalized anxiety and social anxiety disorder (Pande et al., 2004;
Rickels et al., 2005; Tassone et al., 2007). This drug appears to have
a faster onset of anti-anxiety effects than SSRIs and fewer side
effects and lower rates of discontinuation due to adverse events
than benzodiazepines (Feltner et al., 2003; Pande et al., 2003,
2004; Hindmarch et al., 2005; Pohl et al., 2005; Rickels et al., 2005;
Montgomery et al., 2006; Oulis et al., 2008; Lydiard et al., 2010).
Benzodiazepines are thought to exert anxiolytic effects through
modulation of GABAergic neurotransmission (Atack, 2003) and
SSRIs are thought to exert effects primarily throughmodulation of
the 5HT system (Vaswani et al., 2003). PGB’s primary mechanism
ofaction is thought to involve selectivebindingat theα2δ subunitof
voltage-dependent calcium channels, subsequently leading to up-
regulationofGABAinhibitoryactivityandareductionintherelease
of several neurotransmitters, including glutamate, noradrenaline,
serotonin, and substance P (Fink et al., 2002; Dooley et al., 2007;
Brawek et al., 2008). The anxiolytic effects observed for PGB
may, therefore, relate to its eventual effects on neurotransmitter
systems (e.g., serotonin, GABA) that have been implicated in
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anxiety disorders and are influenced by other classes of anxiolytic
medications (e.g., benzodiazepines, SSRIs) (Lydiard, 2003;Millan,
2003; Gordon and Hen, 2004; Lowry et al., 2005; Ebner and
Singewald, 2006; Ravindran and Stein, 2010; Kalk et al., 2011).
Themolecular distinctionbetweenpregabalin and theother agents
(i.e., selectiveactionatvoltage-dependentcalciumchannels)might
explain the selective clinical profile observed with pregabalin (i.e.,
fewer side effects).
Functional magnetic resonance imaging (fMRI) and other
neuroimaging methodologies have been useful for understanding
the neurobiology of anxiety disorders. During symptom provoca-
tion or processing of emotional stimuli, individuals with anxiety
disorders have been reported to exhibit enhanced responsivity
within a neural circuitry centering on themedial prefrontal cortex
(mPFC), anterior cingulate cortex (ACC), insula, and amygdala
(Cannistraro and Rauch, 2003; Etkin and Wager, 2007; Shin and
Liberzon, 2010), though there is somevariability and/or additional
findings depending on the disorder and the particular paradigm
studied. The amygdala has been implicated in the processing of
salience, particularly in response to fear-related stimuli (Davis
and Whalen, 2001; Hariri and Whalen, 2011; Kim et al., 2011),
while the insula is thought to be important for monitoring and
predicting changes in interoceptive state (i.e., internal bodily state)
in response to affective stimuli (Paulus and Stein, 2006; Knutson
and Greer, 2008; Craig, 2011). Medial PFC and ACC regions are
considered important in the integration of affective information,
regulating brain and behavioral responses, and monitoring con-
flict and errors (Ochsner andGross, 2005; Botvinick, 2007; Kanske
et al., 2010; Etkin et al., 2011). In anxiety disorders, prefrontal
regions are theorized to play a role in the regulation of limbic
(e.g., amygdala) activation and in determining the cognitive and
behavioral responses to emotional stimuli (Aupperle and Paulus,
2010; Hofmann et al., 2011; Kim et al., 2011).
It has been proposed that fMRI may also be a viable method
for characterizing neural mechanisms of pharmacologic treat-
ments and as a biomarker for predicting anxiolytic function for
novel agents (Paulus and Stein, 2007). Thus, studies have begun
to investigate the effects of pharmacologic agents on activation
within the prefrontal-insula-amygdala neural circuitry implicated
in anxiety. Much of this research has focused on neural effects
of anxiolytic agents in healthy non-anxious populations, as this
method would be most efficient if used as a biomarker for test-
ing viability of novel pharmacologic agents. fMRI studies with
healthy controls report acute benzodiazepine administration to
be associated with attenuated activation of insula, amygdala,
and mPFC during paradigms involving processing of emotional
faces (Paulus et al., 2005), anticipation of painful stimuli (Wise
et al., 2007), and punishment during risk-based decision-making
(Arce et al., 2006). Sub-chronic SSRI administration (e.g., 3–30
days) has been associated with decreased amygdala, insula, and/or
mPFC and ACC activation during anticipation (Simmons et al.,
2009) and processing of aversive pictures (Takahashi et al., 2005),
and masked and unmasked emotional faces (Del-Ben et al., 2005;
Harmer et al., 2006; Anderson et al., 2007; Arce et al., 2008;
Windischberger et al., 2010).
We previously reported pregabalin to dose-dependently
decreaseactivationwithin insulaandamygdalaand increasemedial
PFCactivationduring anticipationof emotional images (Aupperle
et al., 2011). This study provided initial support for the notion
that anxiolytics, regardless of the molecular mechanism of action
or the direction of influence on prefrontal regions, have the effect
of attenuating amygdala and insula responses during emotional
processing. However, the consistency of pregabalin’s effect on
limbic-prefrontal response patterns for different fMRI paradigms
has not yet been investigated. In the current study, we sought
to investigate whether our previous findings regarding prega-
balin’s effects on neural responses during emotional anticipation
would generalize to emotional face processing, which has been
extensively investigated in relation to limbic function, fear, and
anxietydisorders (Adolphs,2008;Fusar-Poli etal., 2009;Staugaard,
2010). We hypothesized that pregabalin would be associated with
decreased responses within the amygdala and insula specifically
during negative (i.e., angry and fearful) emotional face processing.
MATERIALS ANDMETHODS
PARTICIPANTS AND STUDY DESIGN
Sixteen right handed, healthy volunteers (10 male; mean age =
23.2 ± 2.6 years; nine Caucasian) participated in three scan-
ning sessions in which they were administered placebo, 50mg,
or 200mg doses of pregabalin. This same cohort of subjects has
been reported on previously with a different paradigm (Aupperle
et al., 2011). The specified doses of PGB were chosen in order
to investigate a dose shown to be clinically relevant (200mg)
as compared to a lower dose shown to not produce noticeable
side effects but to not be as clinically effective (50mg) (Feltner
et al., 2003). There was a 1–2 week delay between each test ses-
sion to allow for sufficient elimination of the study drug. The
assignment of placebo or study drug for each session was deter-
mined in a pseudo-randomized order and was administered in a
double-blind fashion. Diagnostic interviews were conducted and
exclusion criteria included satisfying current or life-time DSM-IV
criteria for Axis I or II disorders, current substance abuse or med-
ications, neurological disorders, smoking, or excessive caffeine
consumption (>4 cups/day). All subjects gave written, informed
consent, and were treated in accordance with the Declaration
of Helsinki. The study was approved by the Human Research
Protection Program of the University of California, San Diego.
Subjects performed an event-related version of an emotional
face-matching task adapted from that described by Hariri et al.
(2002) and using emotional faces from the standard NimStim
Set of Facial Expressions (Tottenham et al., 2009) and from
Matsumoto and Ekman (Matsumoto and Ekman, 1988). An
event-related design was used to enable investigation of neural
responses when matching each different face type (happy, fear-
ful, and angry). During each 5 s trial, a target face (on the top
of the computer screen) and two probe faces (on the bottom of
the screen) were presented, and subjects were instructed to match
the probe with the same emotional expression as the target by
pressing the corresponding left or right button. During a control
condition, subjects were instructed to match the target shape to
one of two differently oriented probe shapes. The interstimulus
interval was the period between the subject’s response and the end
of the 5 s trial. The face and shape trials used in this paradigm are
illustrated in Figure 1.
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FIGURE 1 | fMRI emotional face matching task. This task was adapted
from the block-design task described by Hariri et al. (2002) to an
event-related design using the emotional face images from Tottenham et al.
(2009) and Matsumoto and Ekman (1988). This task includes conditions
requiring the subject to match emotional faces or shapes. For the faces
conditions, a target face (on the top of the computer screen) and two probe
faces (on the bottom of the screen) are presented, and subjects are to
match the probe with the same emotional expression to the target by
pressing the corresponding button. For the faces conditions, the subjects
are matching an equal number of angry, fearful, and happy emotional faces.
During the control shape condition, subjects are to match the target shape
to one of two differently oriented probe shapes.
Subjects performed two 8-min runs, each consisting of 24 each
of shapes, happy, sad, and fearful face-matching conditions. Trial
types were presented in a pseudorandom order. Prior to dos-
ing, subjects completed the Karolinska Sleepiness Scale (KSS)
(Akerstedt and Gillberg, 1990), State-Trait Anxiety Inventory-
State version (STAI-T) (Spielberger et al., 1983), and rated their
current state on a Visual Analog Scale (VAS) on the following
dimensions: anxious, embarrassed, tense, tired, dizzy, “high,” ner-
vous and trembling. After completing these baseline measures,
oral doses of pregabalin or placebo were administered with a small
amount of diet coke. Scanning began approximately 1 h after
dosing. Plasma drug concentrations were acquired every 30min
throughout the session. Subjects completed KSS, STAI-S, and the
VAS measures again after the scan.
DATA ACQUISITION
Images were acquired on a 3T GE CXK4 scanner. High-resolution
T1-weighted sagitally acquired anatomical images (SPGR, TR =
20ms, TE = 4.8ms, FOV = 25 cm, approximately 1.5mm3
voxels, 124 slices) were obtained. During the task, whole-brain
BOLD images were acquired with an 8-channel array coil (T2*-
weighted, axially-acquired EPI, 3.43 × 3.43 × 2.6mm3 voxels
with a 1.4mm gap, TR = 2000ms, TE = 32ms, flip angle =
90, 30 slices). Whole-brain images sensitive to arterial spin label-
ing (ASL) were acquired with a PICORE-QUIPSS II (Wong
et al., 1998) sequence with dual-echo spiral acquisition (TE1 =
3ms, TE2 = 30ms), TR = 2000ms, flip angle = 90 degrees,
3.43 × 3.43mm in-plane resolution, five 6mm slices, 20 cm tag
width, 1 cm gap between the tag and the proximal imaging
slice, TI1 = 700ms, TI2 = 1400ms. ASL scans were cali-
brated between subjects and scanning sessions as described in
(Floyd et al., 2003). Proton density of cerebrospinal fluid, a
signal index directly proportional to blood and relatively consis-
tent across time and subjects, was obtained with a single image
through the ventricles at TE = 3ms. ASL scans were included
in the current study to identify pregabalin’s overall effects on
cerebral blood flow (CBF) and to determine whether pregabalin
effects on fMRI BOLD response related to the overall CBF effects.
BEHAVIORAL AND PLASMA DATA ANALYSIS
Linear mixed effects (LME) models were used to examine
the effect of pregabalin dose on behavior, self-report ratings,
and plasma concentrations. LMEs were implemented in R
(www.cran.org), which estimates the parameters of the mixed
model using the Maximum Likelihood Estimation Procedure.
Behavioral data obtained during the scan (CPT reaction time
and accuracy) were subjected to LME analyses with subject as
random effects and pregabalin dose (placebo, 50mg, 200mg pre-
gabalin) and task valence (matching of fearful vs. happy and angry
vs. happy faces) as fixed effects to examine main and interac-
tion effects of each fixed factor. Survey data (KSS, STAI, and VAS
scales) were subjected to LME analyses with subject as random
effects and pregabalin dose and time of self-report (prior to dos-
ing vs. post-scan) as fixed effects in order to examine the dose by
time interaction. To enable further characterization of the effects
observed for dose main effects and dose by valence interaction
effects, post-hoc linearmixedmodels were conducted with specific
contrasts (e.g., PLB vs. 50mg, PLB vs. 200mg, 50mg vs. 200mg),
which were considered significant at the level of p < 0.05.
Plasma concentrations of pregabalin were assessed at National
Medical Services Lab using high performance liquid chro-
matography [HPLC]. The detection limit of this procedure is
0.10mcg/mL. LME analysis was conducted with subject as ran-
dom effects and PGB dose and time of blood draw as fixed effects
in order to examine the main and interaction effects of dose and
time on plasma concentration levels.
fMRI BOLD ANALYSIS
Data were preprocessed and analyzed using Analysis of Functional
NeuroImages (AFNI) software package (Cox, 1996) and R statis-
tical package (r-project.org). All EPI images were aligned to the
high-resolution anatomical images and resampled to a voxel size
of 64μL or 4 × 4 × 4mm (from the original 3.7 × 3.7 × 4mm).
Data were temporally smoothed, spatially blurred with a 4mm
FWHM spatial filter, and normalized to Talairach space (via
AFNI’s auto Talairach program, followed by visual inspection of
each structural image). A signal to noise ratio (SNR) was cal-
culated as the mean signal within amygdala regions of interest
(ROIs) divided by the standard deviation of the mean voxel-wise
signal over time. An SNR greater than two standard deviations
below the sample SNR was used as a cutoff for excluding runs
with poor data quality. One of the two runs for six different scans
was, therefore, excluded from the analysis (leaving one run from
those scans to be included in the analysis). In total, one run each
was excluded for three 50mg sessions, one placebo session, and
two 200mg sessions.
Preprocessed time-series data for each individual were ana-
lyzed using a multiple regression model, based on a BOLD
hemodynamic response function with a 4–6 s peak. Regressors of
interest included three orthogonal regressors used to quantify the
neural activation related to each task component: (1) matching of
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happy faces, (2) matching of fearful faces, (3) matching of angry
faces. Five regressors of no interest were entered into the linear
regression model: three motion-related regressors (for roll, pitch,
and yaw directions), data from a white-matter mask (averaged at
each TR) to control for physiological noise, and a regressor for
linear trends used to eliminate slow signal drifts.
Percent signal change (PSC) was calculated by dividing the
regressor of interest by the control regressor. The trials involving
matching of shapes were not modeled specifically as a regres-
sor of interest but were included as baseline. Therefore, PSC for
all conditions of interest (happy, fearful, angry face-matching)
were compared to an implicit baseline that included both shape-
matching and fixation trials. PSC for happy, angry, and fearful
conditions were subjected to LME analysis in R (www.cran.org).
Separate analyses were conducted to examine task effects and PGB
dose effects on neural activation. First, task effects were identified
within the placebo-treated group only using LMEs with condi-
tion (happy vs. fearful; happy vs. angry faces) as fixed effects and
subject as random effects. Second, PGB dose by valence effects
were examined using an LME with condition (happy vs. fear-
ful; happy vs. angry faces), and dose (placebo, 50mg, 200mg) as
fixed effects and subject as random effects. Third, main effects of
dose on neural activation during each condition type (matching
of happy, fearful, and angry faces) were examined by including
dose (placebo, 50mg, 200mg pregabalin) as fixed effects and sub-
ject as random effects. Finally, an analysis was conducted with test
session number as a covariate to determine whether drug-induced
changes were partially due to the number of sessions an individual
had been in the scanner.
Analyses were conducted voxel-wise across the whole-brain as
well as for specific a priori ROIs using small volume correction.
Bilateral amygdala, mPFC, and anterior insula were selected as
a priori ROIs based on previous literature implicating them in
emotional processing, anticipation, and anxiety disorders. The
fusiform gyrus was included as an a priori region based on pre-
vious literature implicating it to play a primary role in face
processing. These anatomical regions were defined in AFNI using
the ROI plugin and Talairach Atlas (Lancaster et al., 2000) and
are displayed in Figure 2. The mPFC included primarily the
ventral and dorsal ACC; including BA 32, 24, spreading into
ventromedial PFC regions (BA 10). This mPFC region was par-
titioned into dorsal and ventral extents at z = 0, and the anterior
insula was partitioned from the insula as a whole using a lin-
ear interpolation for the location of the middle insular gyrus.
Thus, in total there were eight a priori ROIs (bilateral amygdala,
dorsal and ventral medial PFC, bilateral anterior insula, and bilat-
eral fusiform gyrus). A threshold adjustment method based on
Monte–Carlo simulations (conducted via AFNI’s program Alpha
Sim) was used to guard against identifying false positive areas
of activation. This resulted in the following minimum volumes
for a cluster to be considered significant: 192μL (3 voxels) for
the amygdala ROIs, 256μL (4 voxels) for anterior insula ROIs,
320μL (5 voxels) for medial PFC ROIs, and 832μL (13 vox-
els) for whole-brain analyses. While the cluster significance of
p < 0.05 (two-tailed) was used for all analyses, the corrected
voxel-wise probabilities (determined via AFNI’s program Alpha
Sim) are as follows: amygdala p < 0.0021, anterior insular p <
FIGURE 2 | Regions of interest masks used for fMRI analyses, shown
from axial views. (A) bilateral amygdala (green) and fusiform gyrus (yellow)
(shown at z = −20), (B) bilateral anterior (green) and posterior (yellow)
insula (shown at z = 2), (C) ventral medial prefrontal cortex (PFC; shown at
z = −6), and (D) dorsal medial PFC (shown at z = 4). These anatomical
regions were defined using Talairach Atlas [Lancaster et al. (2000)].
0.0015, posterior insula p < 0.0016, ventromedial PFC and dor-
somedial PFC p < 0.0008, whole-brain p < 0.00001. All reported
coordinates are center of mass Talairach coordinates (x, y, z) and
labeled based on visual observation and Talairach Daemon soft-
ware (Lancaster et al., 2000). For identified activation clusters,
mean F-values were extracted and reported. To enable further
characterization of the effects, PSC was extracted for each acti-
vation cluster and post-hoc linear mixed models were conducted
with specific contrasts (e.g., PLB vs. 50mg, PLB vs. 200mg,
50mg vs. 200mg), which were considered significant at p < 0.05.
Spearman’s non-parametric correlations were used to investi-
gate potential relationships between extracted PSC for significant
clusters and variables that may have influenced BOLD response
including (1) fMRI behavioral data and self-report survey data
significantly influenced by pregabalin (e.g., fMRI paradigm reac-
tion time, KSS, and VAS ratings of dizziness, tired, trembling, and
high) and (2) CBF data collected through ASL (extracted for each
ROI activation cluster identified as significant in fMRI analysis).
These correlations were considered significant at p < 0.05.
fMRI ASL ANALYSIS
ASL scans were reconstructed and CBF was calculated using in-
house scripts in MATLAB (Rack-Gomer et al., 2009). Voxel-based
linear mixed models were completed in R to examine potential
drug effects on CBF. Whole-brain and anatomically constrained
ROI analyses were conducted with these results as described in
the previous section for BOLD data.
RESULTS
PLASMA CONCENTRATION OF PREGABALIN
Plasma concentrations of this sample have been reported on pre-
viously (Aupperle et al., 2011). Briefly, LME analyses revealed
significant effects of dose [F(1, 116) = 250.33, p < 0.001], time
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[F(4, 116) = 14.55, p < .001], and dose by time interaction
[F(4, 116) = 11.69, p < 0.001] on pregabalin plasma concentra-
tions. This indicates that greater dose was associated with greater
plasma concentration levels, that concentration levels increased
with time, and that there was a greater increase in plasma concen-
tration levels for the 200mg than the 50mg dose.
ANALYSIS OF BEHAVIORAL AND SELF-REPORT MEASURES
Pregabalin effects on self-report measures for this cohort have
been reported previously (Aupperle et al., 2011). Briefly, LME
modeling revealed a significant dose by time (pre-dosing vs. post-
scan) effect on ratings of sleepiness [KSS; F(2, 72) = 3.30, p =
0.043; post-hoc analyses revealed (PLB = 50) < 200] and visual
analogue scale (VAS) ratings of feeling dizzy [F(2, 73) = 10.60,
p < 0.001; post-hoc analyses revealed (PLB = 50) < 200], trem-
bling [F(2, 73) = 3.74, p = 0.028; post-hoc analyses revealed 50<
200], high [F(2, 72) = 3.19, p = 0.047; post-hoc analyses revealed
PLB < 200], and tired [F(2, 73) = 3.13, p = 0.050; post-hoc
analyses revealed 50< 200]. Dose had no significant effect on pre-
dosing vs. post-scan ratings of state anxiety [State-Trait Anxiety
Inventory-State subscale (STAI); F(2, 73) = 2.52, p = 0.088], or
VAS ratings related to feeling embarrassed [F(2, 73) = 1.54, p =
0.220], nervous [F(2, 73) = 1.08, p = 0.350], anxious, or tense
(Fs < 1).
Subjects responded with high accuracy [mean = 99% ±
0.05 standard deviation (SD) of the mean] and quickly (mean
response time = 1.33 s ± 0.31 SD) during all sessions and
all four trial types of the emotional face and shape matching
task. LME analyses investigating effects of condition (Face vs.
Shape; Angry vs. Happy; Fear vs. Happy) and dose on accu-
racy revealed that pregabalin was associated with slightly higher
accuracy [F(1, 171) = 4.66; p = 0.011; 200 > PLB], though this
seemed driven by one subject exhibiting slightly lower accuracy
during their placebo scan (while all others were 100% accurate).
There was no effect of condition on accuracy; Shape vs. Face:
[F(2, 171) = 0.049, p = 0.825]; Happy vs. Angry: F(1, 75) =
0.016, p = 0.901; Happy vs. Fear: F(1, 75) = 0.18, p = 0.672 nor
was there a significant dose by condition interaction effect on
accuracy; Face vs. Shape: F(2, 171) = 0.02, p = 0.981; Happy vs.
Angry: F(2, 75) = 0.08, p = 0.924; Happy vs. Fear: [F(2, 75) =
0.18, p = 0.835]. Pregabalin was associated with slower reaction
time across all conditions [F(1, 171) = 5.54, p = 0.005; (200 =
50) > PLB]. There was also a significant difference in reaction
time across conditions, with responses being slower to faces than
shapes [F(1, 171) = 211.62, p < 0.001], slower to angry than
happy faces [F(1, 75) = 52.72, p < 0.001], and slower to fear-
ful than happy faces [F(1, 75) = 39.68, p < 0.001]. There was no
dose by condition interaction effects on reaction time [Face vs.
Shape: F(2, 171) = 0.80; p = 0.451; Happy vs. Angry: F(2, 75) =
0.004, p = 0.996; Happy vs. Fear: F(2, 75) = 0.07, p = 0.930].
See Figure 3 for graphical representation of reaction time across
conditions and doses.
fMRI ANALYSIS
Task effects on BOLD response
Within ROIs, fearful face-matching was associated with greater
activation than happy face-matching within the bilateral fusiform
FIGURE 3 | Pregabalin dose effect on reaction time during fMRI task.
Pregabalin was associated with slower reaction time across face- and
shape-matching conditions [F(1,171) = 14.25, p < 0.001; (200 = 50) > 0].
There was also a significant difference in reaction time across conditions,
with responses being slowest when matching negative emotional faces
than happy faces and slower when matching faces than shapes
[F(2,171) = 183.11, p < 0.001]. There was no significant dose by condition
effect on reaction time [F(2,171) = 0.422, p = 0.656].
gyrus (BA 37), bilateral amygdala/parahippocampal gyrus, and
one region of the subcallosal ACC (BA 25). Happy face-matching
was associated with greater activation than fearful face-matching
within the ACC/medial PFC (BA 32,10). All of these regions,
except the subcallosal ACC cluster (exhibiting Fear > Happy
for ROI analyses) and the insula clusters remained significant
for whole-brain voxel-wise analysis (see Table 1 for full list of
whole-brain results and statistics).
Within ROIs, angry face-matching was associated with greater
activation than happy face-matching within the bilateral fusiform
gyrus (BA 37), bilateral amygdala and PHG, and bilateral ante-
rior/mid insula (BA 13). Happy face-matching was associated
with greater activation than angry within the medial PFC/ACC
(BA 10,32). All of these clusters remained significant for the
whole-brain voxel-wise analysis. See Table 2 for full list of whole-
brain results and statistics. See Figure 4 for task effect results
within region of interests.
Pregabalin effects on BOLD response to emotional faces
There were no clusters for region of interest or whole-brain
analyses that reached significance for the dose by valence inter-
action effect when comparing either fear vs. happy or angry
vs. happy emotional face-matching. Thus, results focus on dose
main effects for each condition type (fearful, angry, and happy
face-matching).
PGB effects during fearful face-matching. Region of interest
analyses. Region of interest analyses revealed that for fearful
face-matching, pregabalin decreased activations within the left
fusiform gyrus [BA 37; PLB > (50 = 200)] and left amygdala
(192 ul; PLB > 200).
Whole-brain analyses. Whole-brain analyses revealed that
200mg pregabalin also increased activations within the right lat-
eral middle frontal (BA 8) and right culmen/lingual gyrus area
(BA 18,19), while the 50mg dose seemed to have unique effects
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Table 1 | Task effect for fMRI emotional face matching task: Fear vs. Happy.
Side Region BA Cluster size (ul) Cluster size (voxels) Mean F Center of mass coordinates (x, y, z)
FEAR > HAPPY
Right fusiform gyrus, middle occipital 18,19,37 35,328 552 12.21 36.2 −76.4 −5.6
Left fusiform gyrus, middle occipital 18,19,37 27,328 427 13.29 −33.3 −77 −9.1
Right dlPFC, middle/inferior frontal 46,9 3776 59 7.63 47.3 28.8 21.9
Left superior parietal, precuneus 7 3328 52 7.14 −26.7 −60 44.7
Right superior/inferior parietal 7 2176 34 7.31 31.5 −58.5 48.3
Left dlPFC; inferior/middle frontal 9,6 1984 31 7.05 −40.1 5.4 30.7
Right dlPFC, middle frontal 9,8 1728 27 8.40 50.7 9.5 37.5
Left dlPFC; middle/inferior frontal 46,45 1600 25 6.59 −50.7 35.8 13.7
Right PHG, extended amygdala 1344 21 7.45 32.3 −7.8 −21.9
Left PHG, amygdala 1152 18 7.63 −25.3 −7.1 −13.3
Right ACC/subcallosal∗ 25 448 7 6.73 2.5 10.3 −9.4
HAPPY > FEAR
Left posterior cingulate, precuneus 31,7 16,000 250 7.97 −1.9 −54.1 20.9
Left superior/middle lateral frontal 8,6 8768 137 11.20 −23.7 22.2 47.4
Left medial PFC/ACC 10,32 5952 93 8.05 −8.6 48.5 5.2
Left inferior parietal, supramarginal 40 5056 79 7.20 −47.1 −63.1 41.1
Left middle temporal 21 4480 70 7.77 −56.1 −32.3 −5.3
Left culmen, PHG 3968 62 7.54 −18.9 −37.6 −8.6
Right inferior parietal, supramarginal 40 3584 56 8.72 54.7 −52 37.2
Right middle/superior frontal 8,6 3584 56 8.35 29.5 25 46.2
Left medial PFC 9,8 1920 30 6.30 0 43.9 28.1
Right cerebellum 1600 25 7.96 19.8 −77.5 −28.9
Left thalamus 1088 17 6.17 −2.2 −23.9 9.4
Left superior temporal, insula 13,22 1024 16 6.79 −46.7 −3.9 −6.1
Left superior temporal 39 960 15 7.03 −45.7 −55.7 25.1
Right postcentral 2 960 15 7.71 39.7 −31.8 40.3
Right cingulate, paracentral 31 960 15 6.52 3.5 −15.9 42.1
Right middle/inferior temporal 20 832 13 7.52 50.7 −27.3 −8.6
Left medial PFC 10 832 13 8.60 −3.3 60.7 3.4
Right IFG, ventral anterior insula∗ 47,13 320 5 7.24 34.4 14.9 −10.6
Left IFG, ventral anterior insula∗ 47,13 320 5 6.10 −33.5 15.4 −8.2
Left IFG, anterior insula∗ 45,13 256 4 4.89 −28 26 0
Regions in which there was a main effect of valence (Fear vs. Happy) on BOLD response during the emotional face matching task.
Notes: ∗Significant only with small volume correction, while all other regions significant in voxel-wise whole-brain analyses; p < 0.05, monte carlo adjusted for
multiple comparisons. All coordinates are Talairach coordinates (x, y, z) based on Talairach Daemon software [Lancaster et al. (2000)]. One voxel is equal to 4 mm3.
Abbreviations: BA, Brodmann area; PHG, parahippocampal gyrus; IFG, inferior frontal gyrus; PFC, prefrontal cortex; dlPFC, dorsolateral PFC; ACC, anterior cingulate
cortex.
from the 200mg dose and was associated with decreased activa-
tions within left superior temporal (BA 13), right inferior parietal
(BA 13), and right lateral and medial frontal cortex (BA 6,8), and
increased activation within left middle frontal cortex (BA 46),
left ACC (BA 25), and right cerebellum. See Table 3 for a full list
of whole-brain voxel-wise results of pregabalin effects on neural
responses to fearful face-matching.
A separate analysis with session number as a covariate revealed
that, with exception of clusters within the ROI fusiform gyrus (BA
37; x, y, z = −36.2,−53.9,−11.8) and the left middle frontal
cortex (BA 46; x, y, z = −46.6, 17.7, 20.4), all clusters remained
significant. See Figure 5 for pregabalin dose effect results within
regions of interest.
PGB effects during angry face-matching. Region of interest
analyses. Region of interest analyses revealed that for angry
face-matching, pregabalin decreased activations within the left
fusiform gyrus [BA 37; PLB > (50 = 200)] and the 50mg
dose decreased activations within the right anterior insula [BA
13; PLB > 50] and increased activation within a region of the
ACC/caudate [BA 25; 50> (0 = 200)].
Whole-brain analyses. Whole-brain analyses revealed that both
doses of pregabalin also decreased activations in left anterior
insula/IFG area (BA13,47), right superior temporal (BA 22), and
left middle temporal cortex (BA 22), and that the 200mg dose
decreased activation within the right dorsal medial frontal cor-
tex (BA 6). The 200mg dose increased activation, while the 50mg
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Table 2 | Task effect for fMRI emotional face matching task: Angry vs. Happy.
Side Region BA Cluster size (ul) Cluster size (voxels) Mean F Center of mass coordinates (x, y, z)
ANGRY > HAPPY
Right fusiform gyrus, middle occipital 18,19,37 53,440 835 14.35 38 −73.3 −4.4
Left fusiform gyrus, middle occipital 18,19,37 42,304 661 16.65 −33.8 −78 −7.6
Right anterior insula, middle/inferior frontal 13,9,6 30,464 476 10.61 44.9 14.8 27.7
Left anterior insula, middle/inferior frontal 13,9,46 23,296 364 10.03 −45.4 19.6 16.5
Right superior dorsomedial frontal 6,8 6720 105 9.22 1.4 12.6 58
Left superior parietal, precuneus 7,40 3712 58 8.48 −28.2 −59.3 44.8
Right superior/inferior parietal 7,40 3264 51 7.87 33 −55.1 51.1
Left superior temporal 22 1600 25 8.18 −60.2 −46.1 12.4
Right dorsal cingulate 24 1408 22 7.79 0.4 3 30.6
Right PHG, amygdala 1216 19 8.67 27.9 1.9 −19
Right PHG, hippocampus 1216 19 8.87 30.7 −20.7 −1.8
Right precuneus, posterior cingulate 7 1088 17 10.10 18.6 −67.7 35
Right dorsal cingulate 32 960 15 7.03 5.6 18.9 31.5
Left PHG, amygdala 832 13 8.10 −25.3 −1.8 −16.3
Right posterior cingulate 23,31 832 13 7.35 1.9 −28.1 29.8
HAPPY > ANGRY
Right medial/superior PFC and ACC 6,10,32 130,112 2033 8.77 0.2 −3.7 33.7
Left cuneus, posterior cingulate 31,18 16,640 260 7.94 −25.2 −50.4 13.5
Left inferior parietal 39,19 3712 58 6.66 −43 −71.1 41.7
Right inferior parietal, angular gyrus 39,40 3392 53 8.50 47.3 −65.1 44.6
Right precuneus, posterior cingulate 31,30 2816 44 6.43 13 −49.8 25.3
Right posterior insula, superior temporal 41,13 2688 42 6.72 49.9 −19.3 14.8
Right cerebellum 1152 18 7.76 36.5 −59.1 −38.8
Right inferior parietal 40 1088 17 6.80 55.4 −38.6 43.9
Right cuneus 18 896 14 6.72 14.4 −84.1 24
Left superior temporal 22 832 13 6.57 −58.4 −6.7 7
Regions in which there was a main effect of valence (Angry vs. Happy) on BOLD response during the emotional face matching task.
Notes: All regions significant in voxel-wise whole-brain analyses, p < 0.05, Monte–Carlo adjusted for multiple comparisons. All coordinates are Talairach coordinates
(x, y, z) based on Talairach Daemon software [Lancaster et al. (2000)]. One voxel is equal to 4 mm3. Abbreviations: BA, Brodmann area; PHG, parahippocampal gyrus,
IFG, inferior frontal gyrus, PFC, prefrontal cortex.
dose decreased activation within the left dorsolateral PFC (BA 9).
The 50mg dose was additionally associated with increased activa-
tion within left superior parietal (BA 7), right postcentral gyrus
(BA 5 and 3), and left dorsal cingulate (BA 24). See Table 4 for a
full list of whole-brain voxel-wise results of pregabalin effects on
neural responses to angry face-matching.
A separate analysis with session number as a covariate revealed
that, with the exception of a cluster within the fusiform gyrus
(BA 37; x, y, z = 43, 55,−16), all clusters remained significant.
See Figure 5 for pregabalin dose effect results within regions of
interest.
PGB effects during happy face-matching. Region of interest
analyses. There were no consistent dose effects identified within
ROIs for happy face-matching. The 50mg dose had the unique
effect of increasing activation within the right fusiform gyrus (BA
37) and left medial PFC/ACC (BA 32,10).
Whole-brain analyses. Whole-brain analyses revealed that the
200mg dose increased activation within the right inferior parietal
(BA 40,2) while the 50mg dose increased activation within the
right superior middle frontal (BA 46,10), right middle cingulate
(BA 24,23), left IFG (BA 44), and right cerebellum, and decreased
activation within the right middle/inferior temporal (BA 37,19).
The 50mg pregabalin dose increased activation within the left
superior middle frontal (BA 10,11) while the 200mg dose
decreased activation in this region. See Table 5 for a full list of
whole-brain voxel-wise results.
A separate analysis with session number as a covari-
ate resulted in clusters within the right cerebellum (x, y, z =
8.7,−52,−39.6), left IFG (BA 44; x, y, z = −41.9, 16.7, 16.2),
right superior middle frontal (BA 46,10; x, y, z = 53.7, 44.3, 3.4),
right middle cingulate (BA 24,23; x, y, z = 4.9,−19, 37.6),
and middle/inferior temporal cortex (BA 37,19; x, y, z =
47.9,−63.2, 2.1) to no longer reach significance. All other
reported clusters remained significant.
ASL ANALYSIS
Results from LME analysis investigating effects of pregabalin on
CBF have been reported previously for this cohort (Aupperle
et al., 2011) and showed PGB to be associated with increased
CBF within the left ventral ACC only [F(2, 24) = 6.803, p <
0.005,−12, 40, 2; post-hoc test revealed 50mg > PLB]. CBF was
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FIGURE 4 | Task valence effect on fMRI BOLD activation. Regions within
bilateral fusiform gyrus (A) and bilateral amygdala (B) showed greater
activation for both fearful and angry faces compared to happy. Bilateral
anterior insula also showed greater activation for angry compared to happy
faces (D2) but showed greater activation to happy compared to fearful faces
(D1). Regions of the mPFC exhibited greater activation for happy compared
to both angry and fearful faces (C). Graphs depicted below each image
represent average PSC for negative (fearful or angry) and happy conditions.
extracted for each cluster identified as significant in the fMRI ROI
analyses discussed above to investigate correlations with fMRI
PSC. For those ROI clusters identified as being significantly influ-
enced by dose effect for angry, fear, or happy face-matching, there
were no correlations between ASL, CBF, and PSC (all p-values >
0.100).
fMRI BOLD AND BEHAVIORAL MEASURES
To determine whether pregabalin effects on BOLD activation in
ROIs related to its effects on subjective ratings or task behav-
ior, correlational analyses were conducted with extracted PSC
for the ROI activation clusters discussed previously and each
behavioral and self-report measure also shown to be influ-
enced by pregabalin. For happy face-matching, there were neg-
ative correlations between change in VAS ratings of “trembling”
(post-scan – pre-dosing) and the mid ACC (BA 32,10; 384 ul)
cluster from ROI analyses (rho = −0.328, p = 0.023). For fearful
face-matching, there was a negative correlation between change
in VAS ratings of “trembling” and the amygdala cluster (rho =
−0.394, p = 0.006). These results indicate that subjects who were
experiencing greater feelings of trembling, exhibited less neural
activation in these regions. For angry face-matching, there were
no correlations between ROI clusters of activation and behavioral
or self-report measures (all p-values< 0.100).
DISCUSSION
Pregabalin was found to dose-dependently decrease left amyg-
dala response to fearful faces and left anterior insula/inferior
frontal gyrus response to angry faces. These effects are similar to
previous studies reporting benzodiazepines and SSRIs to decrease
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Table 3 | Pregabalin dose effect on fMRI emotional face matching task: Fear Faces.
Side Region BA Cluster Cluster size Mean F Center of mass coordinates (x, y, z) Post-hoc
size (ul) (voxels) dose effects
Left fusiform gyrus, declive∗ 37 512 8 4.57 −36.2 −53.9 −11.8 0 > [50 = 200]
Left PHG, amygdala∗ 192 3 3.93 −16 −6.8 −11.2 0 > 200
Right lateral middle frontal 8 896 14 4.66 31.8 39.5 44.9 200 > [0 = 50]
Right culmen, lingual gyrus 18,19 832 13 4.28 9 −60.8 −0.6 200 > [0 = 50]
Left IFG, superior temporal 47 2432 38 5.00 −48 22.9 −4.4 50 > 0 > 200
Right Lateral middle frontal
spreading to medial
PFC/ACC
8,6,9 3136 49 5.37 23.2 24.6 26.7 [0 = 200] > 50
Left superior temporal, inferior
parietal
13 1984 31 4.69 −35.4 −44 20.5 [0 = 200] > 50
Right inferior parietal,
supramarginal
13 1088 17 4.72 39.7 −43.3 25.2 [0 = 200] > 50
Right lateral precentral 6 960 15 4.65 52.6 −8.3 29.3 [0 = 200] > 50
Right medial frontal 6 832 13 4.92 16.4 1.2 62.4 [0 = 200] > 50
Left middle frontal, IFG 46 1216 19 4.82 −46.6 17.7 20.4 50 > [0 = 200]
Right cerebellum 1152 18 4.47 26 −75.4 −28.7 50 > [0 = 200]
Left ACC, medial PFC 25 832 13 5.46 −12.4 26.7 −7.8 50 > [0 = 200]
Regions in which there was a pregabalin dose main effect on BOLD response during trials in which subjects were matching fearful emotional faces.
Notes: ∗Significant only with small volume correction, while all other regions significant in voxel-wise whole-brain analyses, p < 0.05, Monte–Carlo adjusted for
multiple comparisons. All coordinates are Talairach coordinates (x, y, z) based on Talairach Daemon software [Lancaster et al. (2000)]. One voxel is equal to 4 mm3.
Abbreviations: BA, Brodmann area; PHG, parahippocampal gyrus; IFG, inferior frontal gyrus; PFC, prefrontal cortex; ACC, anterior cingulate cortex.
Table 4 | Pregabalin dose effect on fMRI emotional face matching task: Angry Faces.
Side Region BA Cluster Cluster size Mean F Center of mass coordinates (x, y, z) Post-hoc
size (ul) (voxels) dose effects
Right superior temporal 22 3072 48 5.49 59.5 −41.5 15.4 0 > [50 = 200]
Left fusiform gyrus, declive 37 1216 19 4.17 −42.8 −55.5 −16.8 0 > [50 = 200]
Left IFG, anterior insula 47,13 1216 19 4.46 −43.5 21.3 2.2 0 > [50 = 200]
Right dorsal medial frontal 6 2304 36 4.93 3.9 −10.9 62.6 [0 = 50] > 200
Left middle temporal 22 832 13 4.78 −56.8 −37.7 3 0 > 50 > 200
Left middle/superior frontal 9 1152 18 4.81 −34 45.7 34.3 200 > 0 > 50
Left postcentral, superior parietal 7 2048 32 4.76 −19.9 −48.7 63.9 50 > [0 = 200]
Right cerebellum 1600 25 4.56 4.2 −48.9 −40.2 50 > [0 = 200]
Right postcentral gyrus 5 960 15 5.24 21.2 −41.9 66.6 50 > [200 = 0]
Right postcentral/paracentral
gyrus
3 832 13 4.93 13.2 −35.4 70.5 50 > [0 = 200]
Right ACC, caudate∗ 25 384 6 4.43 6.7 17.5 −3.5 50 > [0 = 200]
Left dorsal cingulate 24 1024 16 6.00 −0.3 2.6 24.4 50 > 0
Right anterior insula, IFG 13 1536 24 4.81 34 18.5 7.4 [0 = 200] > 50
Regions in which there was a pregabalin dose main effect on BOLD response during trials in which subjects were matching angry emotional faces.
Notes: ∗Significant only with small volume correction, while all other regions significant in voxel-wise whole-brain analyses, p < 0.05, Monte–Carlo adjusted for
multiple comparisons. All coordinates are Talairach coordinates (x, y, z) based on Talairach Daemon software [Lancaster et al. (2000)]. One voxel is equal to 4 mm3.
Abbreviations: BA, Brodmann area; PHG, parahippocampal gyrus; IFG, inferior frontal gyrus; PFC, prefrontal cortex; ACC, anterior cingulate cortex.
amygdala and/or insula activation during emotional face pro-
cessing (McKie et al., 2005; Paulus et al., 2005; Harmer et al.,
2006; Anderson et al., 2007; Arce et al., 2008; Windischberger
et al., 2010). In addition, they are consistent with our previ-
ous report that pregabalin dose-dependently decreases amygdala
and insula activation during anticipation of emotional images
(Aupperle et al., 2011). Despite their unique neuronal mecha-
nisms of action, evidence collected from the current and previous
studies suggests that benzodiazepines, SSRIs, and pregabalin may
share a common regional brain mechanism—namely, the atten-
uation of insula and/or amygdala activation during emotional
processing. This supports the potential for fMRI to be used as a
Frontiers in Human Neuroscience www.frontiersin.org March 2012 | Volume 6 | Article 42 | 9
Aupperle et al. Pregabalin effects on neural response
Table 5 | Pregabalin dose effect on fMRI emotional face matching task: Happy Faces.
Side Region BA Cluster Cluster size Mean F Center of mass coordinates (x, y, z) Post-hoc
size (ul) (voxels) dose effects
Right inferior parietal, postcentral 40,2 1152 18 4.62 55.6 −30.2 43.8 200 > [0 = 50]
Left superior middle frontal,
ventrolateral PFC
10,11 1664 26 4.13 −39 51.3 −9.5 50 > 0 > 200
Right cerebellum 960 15 4.14 8.7 −52 −39.6 50 > [0 = 200]
Left IFG 44 896 14 4.78 −41.9 16.7 16.2 50 > [0 = 200]
Right superior middle frontal, IFG,
ventrolateral PFC
46,10 1536 24 4.29 53.7 44.3 3.4 50 > [0 = 200]
Right middle cingulate 24,23 832 13 4.07 4.9 −19 37.6 50 > [0 = 200]
Right fusiform gyrus∗ 37 448 7 4.40 41.1 −52 −14 50 > [0 = 200]
Left mid ACC, medial PFC∗ 32,10 384 6 3.95 −4 46.7 1.3 50 > [0 = 200]
Right middle/inferior temporal 37,19 960 15 4.78 47.9 −63.2 2.1 [200 = 0] > 50
Regions in which there was a pregabalin dose main effect on BOLD response during trials in which subjects were matching happy emotional faces.
Notes: ∗Significant only with small volume correction, while all other regions significant in voxel-wise whole-brain analyses, p < 0.05, Monte–Carlo adjusted for
multiple comparisons. All coordinates are Talairach coordinates (x, y, z) based on Talairach Daemon software [Lancaster et al. (2000)]. One voxel is equal to 4 mm3.
Abbreviations: BA, Brodmann area; PHG, parahippocampal gyrus; IFG, inferior frontal gyrus; PFC, prefrontal cortex; ACC, anterior cingulate cortex.
FIGURE 5 | Pregabalin effect on fMRI BOLD activation during
processing of fear and angry emotional faces. For fear faces,
pregabalin was associated with a consistent decrease in left amygdala
[0 > (50 = 200); identified via region of interest (ROI) analyses] activation
while 50mg pregabalin increased ventral ACC activation (identified via
whole-brain analyses). For angry faces, pregabalin was associated
with a consistent decrease in a region of the left anterior insula/inferior
frontal gyrus [B2; 0 > (50 = 200); identified via whole-brain analyses]
while 50mg pregabalin decreased right anterior insula activation
[B1; (0 = 200) > 50; identified via ROI analyses] and increased ventral
ACC activation [B3; 50 > (0 = 200); identified via ROI analyses].
Graphs depicted with each image represent average PSC for
negative emotional faces for each dose (placebo, 50mg, and 200mg
pregabalin).
Frontiers in Human Neuroscience www.frontiersin.org March 2012 | Volume 6 | Article 42 | 10
Aupperle et al. Pregabalin effects on neural response
biomarker for detecting or predicting anxiolytic effects of current
and novel agents and suggest that continued research to further
this endeavor is warranted.
It is interesting to note that pregabalin exhibited significant
effects on the amygdala during fearful face-matching but on
the insula during angry face-matching. This must be consid-
ered in the context of our task effect findings, in which angry
faces activated anterior insula greater than happy faces whereas
the opposite pattern was found for fearful faces. A recent meta-
analyses of fMRI findings related to emotional face processing
found that while amgydala activation was significant for happy,
fearful, and sad faces, insula activation was instead significant
for angry and disgust faces (Fusar-Poli et al., 2009). While the
amygdala is thought to be important for processing stimuli
that are emotionally salient or that have reinforcement value
(Davis and Whalen, 2001; Morrison and Salzman, 2010), the
insula is considered important for monitoring the internal bodily
state and potentially predicting future changes in somatosen-
sory state (Critchley et al., 2004; Craig, 2009). Perhaps seeing
angry faces produces increased internal monitoring or hyper-
vigilance, i.e., to examine if there is anything “wrong,” whereas
fearful faces instead provoke more of an external hypervigilance.
Given that the insula and amygdala may play different roles
during processing of emotional stimuli and situations, it is poten-
tially important that pregabalin (and other anxiolytics) influences
responses within both of these regions in response to relevant
contexts. On the other hand, if future pharmacologic agents were
able to selectively target specific emotional processes and brain
regions, treatment may be able to be tailored for different types of
anxiety symptoms.
Perhaps the most surprising finding in the current study was
that the 50mg dose of pregabalin seemed to exhibit more robust
effects than the 200mg dose in many different regions. For exam-
ple, the 50mg dose increased responses within the ventral ACC
for both angry and fearful faces and decreased activation within
the right anterior insula to angry faces, while the 200mg dose
seemed to normalize responses in these regions to placebo levels.
Notably, the clinical literature suggests that while 200mg doses
of PGB are effective in the treatment of anxiety (Feltner et al.,
2003; Pohl et al., 2005), doses of 50–150mg have minimal clin-
ical benefit (Feltner et al., 2003; Pande et al., 2004). The 50mg
dose was therefore not expected to exhibit stronger effects on neu-
ral activation than the 200mg dose. One could postulate that the
50mg dose, while not clinically beneficial for anxiety patients, is
a more appropriate “anxiolytic” dose for the healthy control sub-
jects used in this study. However, these explanations are unlikely
to be the primary reason for these findings given that more con-
sistent pregabalin dose effects were found for this same cohort
and same dosing levels using an emotional anticipation paradigm
(Aupperle et al., 2011). The inconsistent dose effects could also
relate to there being a “just right” phenomenon concerning prega-
balin dosing, with 50mg somehow producing neural effects that
are “too much” and do not produce as much clinical benefit as the
more tempered effects of the 200mg dose. These results could also
point to a potential disconnect between dose-dependent effects
of pregabalin on clinical symptoms and effects on brain activa-
tion. Notably, the emotional face processing paradigm used in
the current study is thought to be most sensitive to amygdala
function (Hariri et al., 2002; Adolphs, 2008; Fusar-Poli et al.,
2009; Staugaard, 2010) and pregabalin exhibited a consistent dose
effect on amygdala response to fearful faces. Thus, it may be that
attenuation of amygdala response is the most relevant biomarker
for this specific paradigm, with effects on other regions being
less clinically relevant. Future research examining the relationship
between acute or sub-chronic brain effects (during various emo-
tional processing paradigms) and longer-term clinical effects of
pregabalin in the same population is needed to clarify the dose
effects found in the current study.
The current study had several limitations. First, it investi-
gated neural effects of acute PGB administration. Clinical trials
with pregabalin have reported symptom reduction within as early
as 4 h post-administration (Feltner et al., 2003). However, it is
possible that acute and chronic doses of pregabalin have dif-
ferent effects on neural response patterns. Future investigations
regarding neural effects of chronic pregabalin would be useful
in extending the current findings. The strength of the current
study is that it examined the effects of different doses of PGB
as compared to placebo in the same group of subjects. However,
this could also be considered a limitation in that it required
repeated administration of the same anticipation paradigm and,
therefore, could have been influenced by habituation or sensitiza-
tion effects. Although the ROI results reported remained largely
unchanged when including session as a covariate, there remains
the potential that repeated testing influenced results. In addition,
the subjects included in this study were healthy controls without
any psychiatric diagnosis. Individuals with anxiety disorders have
been shown to exhibit greater activation within insula and amyg-
dala regions compared to healthy controls during emotional face
processing tasks (Stein et al., 2002, 2007; Shin et al., 2005). We
would, therefore, expect that the effects of pregabalin on activa-
tion within these regions may be even more pronounced than in
the current study. However, given that many of the dose effects
observed in this study were inconsistent with what is known
regarding clinical dosing with pregabalin, it is possible that pre-
gabalin’s effects differ depending on the psychological state of
the individual. Future research investigating pregabalin effects on
neural activation of anxiety disorder patients is needed to clarify
the clinical implications of the current findings and the viabil-
ity of using fMRI to characterize and predict anxiolytic treatment
effects.
CONCLUSIONS
The current study found pregabalin to dose-dependently decrease
left insula and amygdala responses during processing of neg-
ative emotional faces, similar to what was found previously
for anticipation of emotional images. This lends support to
the notion that fMRI may prove to be a useful biomarker
for characterizing and predicting anxiolytic potential of phar-
macologic agents. However, pregabalin also produced dose-
inconsistent effects within insula, anterior cingulate, and other
regions, in which the 50mg dose seemed to have a more robust
effect than the more clinically-relevant 200mg dose. This indi-
cates that further research is needed to determine the clinical
relevance of pharmaco-fMRI findings to different dosings of
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anxiolytic agents and to healthy control versus anxiety disorder
populations.
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